Mexico
Hepatitis B
Download HBV dataHBV National Action Plan
HBV elimination goal
National prevalence survey within the last 5 years
Partially Adopted
Estimates of economic burden
Not Adopted
HepB birth dose policy
Yes
Year of birth dose introduction
2005
Recommendations for HBV testing of pregnant women
Partially Adopted
Eligible for HBV generic medicines
Licensed point-of-care PCR testing to detect HBV
Partially Adopted
No patient co-pays for HBsAg testing
Partially Adopted
Adult HBV vaccination policy for high-risk populations
Adopted
Public budget line for testing and treatment
Adopted
HCV National Action Plan
HCV elimination goal
HCV elimination goal
2030
National prevalence survey within the last 5 years
Partially Adopted
Estimates of economic burden
Not Adopted
System for monitoring testing and treatment
Partially Adopted
Recommendations for HCV testing of pregnant women
Adopted
Registration of originator HCV DAAs
Adopted
Registration of generic HCV DAAs
Not Adopted
Licensed point-of-care PCR testing to detect HCV
Partially Adopted
No patient co-pays for anti-HCV testing
Partially Adopted
HCV testing policy
Risk-based
National treatment guidelines exist
Adopted
Simplified care: Non-specialists can prescribe treatment
Adopted
Simplified care: No treatment co-pays
Adopted
No fibrosis restrictions
Adopted
No sobriety restrictions
Adopted
National policy for harm reduction for persons who inject drugs
Partially Adopted
National policy for syringe exchange in federal prisons
Not Adopted
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
OST in at least one prison
No
Decriminalization of possession of syringes and paraphernalia
Adopted
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)
Public budget line for testing and treatment
Adopted
Hepatitis C
Download HCV dataHBV National Action Plan
HBV elimination goal
National prevalence survey within the last 5 years
Partially Adopted
Estimates of economic burden
Not Adopted
HepB birth dose policy
Yes
Year of birth dose introduction
2005
Recommendations for HBV testing of pregnant women
Partially Adopted
Eligible for HBV generic medicines
Licensed point-of-care PCR testing to detect HBV
Partially Adopted
No patient co-pays for HBsAg testing
Partially Adopted
Adult HBV vaccination policy for high-risk populations
Adopted
Public budget line for testing and treatment
Adopted
HCV National Action Plan
HCV elimination goal
HCV elimination goal
2030
National prevalence survey within the last 5 years
Partially Adopted
Estimates of economic burden
Not Adopted
System for monitoring testing and treatment
Partially Adopted
Recommendations for HCV testing of pregnant women
Adopted
Registration of originator HCV DAAs
Adopted
Registration of generic HCV DAAs
Not Adopted
Licensed point-of-care PCR testing to detect HCV
Partially Adopted
No patient co-pays for anti-HCV testing
Partially Adopted
HCV testing policy
Risk-based
National treatment guidelines exist
Adopted
Simplified care: Non-specialists can prescribe treatment
Adopted
Simplified care: No treatment co-pays
Adopted
No fibrosis restrictions
Adopted
No sobriety restrictions
Adopted
National policy for harm reduction for persons who inject drugs
Partially Adopted
National policy for syringe exchange in federal prisons
Not Adopted
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
OST in at least one prison
No
Decriminalization of possession of syringes and paraphernalia
Adopted
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)
Public budget line for testing and treatment
Adopted
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
No data available
Hepatitis related deaths (national)
Modelled
HBV
2,125
2019
(1,714 - 2,622)
IHME, GBD 2019 (accessed 2020)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
13,737
2019
(11,294 - 16,865)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.03
(%)
2020, latest modelled
(0.02 - 0.04(%))
WHO
Eligible for HBV generic medicines
Elimination champion
